Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with disease-related biomarkers

Journal of Alzheimer's Disease

Volumn 43, Issue 3, 2015, Pages 835-847

  Ivanoiu, Adrian ^a,b   Dricot, Laurence ^b   Gilis, Nathalie ^a   Grandin, Cécile ^a,b   Lhommel, Renaud ^a   Quenon, Lisa ^b   Hanseeuw, Bernard ^a,b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Alzheimer's disease; biological markers; early diagnosis; mild cognitive impairment

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; FLUTEMETAMOL F 18;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CLINICAL CLASSIFICATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EXECUTIVE FUNCTION; FEMALE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL INSTITUTE ON AGING ALZHEIMER ASSOCIATION CRITERIA; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; DISEASE COURSE; EARLY DIAGNOSIS; MIDDLE AGED; PATHOLOGY; PSYCHOLOGY; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BIOMARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 84914693619     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140651     Document Type: Article

References (47)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
2. Reisberg B, Prichep L, Mosconi L, John ER, Glodzik-Sobanska L, Boksay I, Monteiro I, Torossian C, Vedvyas A, Ashraf N, Jamil IA, de Leon MJ (2008) The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease. Alzheimers Dement 4, S98-S108.
3. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, TierneyMC, Whitehouse P,Winblad B, International Psychogeriatric Association Expert Conference on mild cognitive impairment (2006) Mild cognitive impairment. Lancet 367, 1262-1270.
4. Petersen RC, Negash S (2008) Mild cognitive impairment: An overview. CNS Spectr 13, 45-53.
5. Ritchie K, Artero S, Touchon J (2001) Classification criteria for mild cognitive impairment:Apopulation-based validation study. Neurology 56, 37-42.
6. Fisk JD, Rockwood K (2005) Outcomes of incident mild cognitive impairment in relation to case definition. J Neurol Neurosurg Psychiatry 76, 1175-1177.
7. Maioli F, Coveri M, Pagni P, Chiandetti C, Marchetti C, Ciarrocchi R, Ruggero C, Nativio V, Onesti A, D'Anastasio C, Pedone V (2007) Conversion of mild cognitive impairment to dementia in elderly subjects:Apreliminary study in a memory and cognitive disorder unit. Arch Gerontol Geriatr 44(Suppl 1), 233-241.
8. Stewart R (2012) Subjective cognitive impairment. Curr Opin Psychiatry 25, 445-450.
9. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262.
10. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
11. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319.
12. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM, Alzheimer's Disease Neuroimaging Initiative (2010) Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 6, 230-238.
13. Atiya M, Hyman BT, Albert MS, Killiany R (2003) Structural magnetic resonance imaging in established and prodromal Alzheimer disease: A review. Alzheimer Dis Assoc Disord 17, 177-195.
14. Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131, 665-680.
15. Karow DS, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr, Jennings RG, Brewer JB, Hoh CK, Dale AM, Alzheimer's Disease Neuroimaging I (2010) Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology 256, 932-942.
16. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL,WeinerMW, Jagust WJ, Alzheimer's Disease Neuroimaging I (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32, 1207-1218.
17. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
18. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844.
19. Carrillo MC, Dean RA, Nicolas F, Miller DS, Berman R, Khachaturian Z, Bain LJ, Schindler R, Knopman D (2013) Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria. Alzheimers Dement 9, 594-601.
20. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSMIV-TR®), American Psychiatric Association, Washington, DC.
21. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
22. Manolio TA, Kronmal RA, Burke GL, Poirier V, O'Leary DH, Gardin JM, Fried LP, Steinberg EP, Bryan RN (1994) Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. Stroke 25, 318-327.
23. Van der Linden M, Coyette F, Poitrenaud J, Kalafat M, Calicis F, Wyns C, Adam S, et les membres du GREMEM (2004) L'épreuve de rappel libre/rappel indicé à 16 items (RL/RI-16) In L'évaluation des troubles de la mémoire: Présentation de quatre tests demémoire épisodique (avec leur étalonnage), Van der Linden Mec, ed, Solal, Marseille.
24. de Partz MP, Bilocq V, DeWilde V, Seron X, Pillon A (2001) LEXIS: Tests pour l'évaluation des troubles lexicaux chez la personne aphasique, Solal Editeurs, Marseille.
25. Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K (1992) Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn 18, 70-87.
26. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A (1988) Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 24, 641-652.
27. FreeSurfer, Martinos Center for Biomedical Imaging, Boston, MA, USA, http://surfer.nmr.mgh.harvard.edu/
28. Dale AM, Fischl B, Sereno MI (1999) Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 9, 179-194.
29. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van derKouwe A, Killiany R,Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM (2002) Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341-355.
30. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D, Caviness V, Makris N, Rosen B, Dale AM (2004) Automatically parcellating the human cerebral cortex. Cereb Cortex 14, 11-22.
31. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ (2010) 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 68, 319-329.
32. Pmod Technologies Ltd Z, Statistical Parametric Mapping, http://www.fil.ion.ucl.ac.uk/spm/software/spm5/
33. Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Nagren K, Darcourt J, Kapucu OL, Tatsch K, Bartenstein P, Van Laere K, European Association of Nuclear Medicine NeuroimagingC(2009)EANMprocedure guidelines for PET brain imaging using[18F]FDG, version 2. Eur J Nucl Med Mol Imaging 36, 2103-2110.
34. Herholz K, Westwood S, Haense C, Dunn G (2011) Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med 52, 1218-1226.
35. Haense C, Herholz K, Jagust WJ, Heiss WD (2009) Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI). Dement Geriatr Cogn Disord 28, 259-266.
36. Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, LoweV, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC(2012)Anoperational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71, 765-775.
37. MedCalc, MedCalc Software, http://www.medcalc.org/index.php
38. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, Schonknecht P, Ito K, Mielke R, Kalbe E, Zundorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schroder J, Kato T, Arahata Y, Henze M, Heiss WD (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17, 302-316.
39. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6, 67-77.
40. Mulder ER, de Jong RA, Knol DL, van Schijndel RA, Cover KS, Visser PJ, Barkhof F, Vrenken H, Alzheimer's Disease Neuroimaging I (2014) Hippocampal volume change measurement: Quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. Neuroimage 92, 169-181.
41. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ, Alzheimer's Disease Neuroimaging I (2013) The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 9, e111-e194.
42. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging B, Lifestyle Research G (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367.
43. Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL, Group AR (2012) Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: A voxelwise PiB-PET longitudinal study. Brain 135, 2126-2139.
44. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
45. Mukherjee S, Trittschuh E, Gibbons LE, Mackin RS, Saykin A, Crane PK, Azheimer's Disease Neuroimaging I (2012) Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: Relationships with SNPs in ADNI. Brain Imaging Behav 6, 649-660.
46. Dickerson BC, Wolk DA, Alzheimer's Disease Neuroimaging I (2011) Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry 82, 45-51.
47. Tucker AM, Stern Y (2011) Cognitive reserve in aging. Curr Alzheimer Res 8, 354-360.